

**Informational brochure
regarding a clinical study
involving AGLE-102™ in
individuals living with RDEB**

AEGLE
THERAPEUTICS

400 Trade Center, Suite 5900
Woburn, MA 01801

Copyright © 2015 – 2024 AEGLE Therapeutics


**AEGLE
THERAPEUTICS**

AEGLE Therapeutics is a clinical-stage biotechnology company developing novel extracellular vesicle (“EV”) therapies to address rare and serious diseases

www.aegletherapeutics.com

What is AGLE-102™?

AGLE-102™ is an investigational product composed of **native extracellular vesicles (EVs)** isolated from allogeneic stem cells. AGLE-102™ is a topical agent being developed as a potential treatment for severe dermatological and immune based disorders, including RDEB.



EVs are cell messengers your body uses to deliver important biomolecules, such as the protein collagen 7, to promote healing.

Why are EVs important?

The EVs in AGLE-102™ are naturally derived from mesenchymal stem cells (MSCs) -- special cells in your body that can act like **repair crews** and have the power to help fix and regenerate different tissues. MSC-derived EVs carry the biomolecules that are responsible for the action of MSCs.

MSC-EVs possess important **immunomodulatory properties**, which means they can regulate activities of the immune system to reduce inflammation and suppress immune responses. These actions are essential for **wound healing** and help your body fight disease.

The ability of EVs to **deliver important biomolecules** such as proteins and nucleic acids offers the potential to repair defects associated with serious disease.

Are you considering participating in the AGLE-102™ clinical study for RDEB?

- This trial is recruiting **Recessive Dystrophic Epidermolysis Bullosa (RDEB)** participants
- The first 2 participants must be **≥18 years of age**
- Enrollment is projected to include participants **≥6 years of age in the 2nd quarter of 2024**
- **One chronic wound will be selected for treatment with AGLE-102™**
- Eligible participants will receive up to **6 topical treatments of AGLE-102™ over a period of 10 weeks**
- **Safety will be followed for 12 weeks from end of treatment**
- **Compensation to support travel to the clinical trial site will be offered**

We are committed to ensuring participant confidentiality. Privacy will be protected, and all personal information will be handled securely.

We understand that participating in a clinical trial is an important decision for you and your family. Your / your child's participation will generate results that can help change the way RDEB is managed and potentially pave the way for future therapies to help those living with this disease.

Contact information | Clinical trial participants

If you have questions regarding the RDEB AGLE-102™ clinical trial, or if you are interested in participating, please contact:

Principal Investigator
Dr. David T. Woodley

Contact Person
Mei Chen, PhD

Department of Dermatology
USC/Norris Comprehensive Cancer Center
University of Southern California
1441 Eastlake Avenue, Room 6322
Los Angeles, CA 90033



Phone: (323) 865-0621



Email: chenm@usc.edu

Additional sites will be coming mid 2024 once the first 2 adults have completed treatment.

For more information about | AEGLE Therapeutics

Visit our website at
www.AegleTherapeutics.com